Search results “Basal b breast cancer”
Advancing Our Understanding of Basal-Like, Luminal A, and Luminal B Breast Cancers
Christopher Li, M.D., Ph.D. of the Fred Hutchinson Cancer Research Center is a CDMRP-funded investigator supported by the DoD Breast Cancer Research Program (BCRP). Dr. Li is collaborating with Dr. Arul Chinnaiyan of the University of Michigan to analyze the tumor genome of triple negative breast cancer and other breast cancer subtypes to identify risk and prognostic factors that could have an impact on prevention and treatment strategies.
Views: 712 CDMRP
Neil Barth, Agendia: Molecular Subtypes in Breast Cancer Challenging the Clinical Subtyping Paradigm
Neil Barth, M.D., Chief Medical Officer, Agendia Gene profiling of early stage breast cancers has become more common place. The emergence of this technology for improving selection of patients for therapy is challenging the paradigm of IHC/FISH based clinical subtypes. Functional molecular subtyping reclassifies approximately one third of all early sage breast cancer patients and more accurately assigns them to more (basal-like) or less (luminal-like) chemotherapy sensitive categories. This has significant implications for neo-adjuvant treatment selection. For more information go to PMWCintl.com
Views: 1045 PMWCintl
Managing Luminal A and Luminal B Breast Cancer
The panelists, Adam Brufsky, MD; Joyce O’Shaughnessy, MD; Christy Russell, MD; Hope Rugo, MD; and Sara Hurvitz, MD, share new data regarding the management of luminal A and luminal B breast cancer.
Views: 1469 OncLiveTV
Dr. Aithal on Breast Cancer Subtypes
Sramila Aithal, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses breast cancer subtypes. There are four molecular subclasses of breast cancer: luminal A, luminal B, basal-like or triple-negative, and HER2-enriched. Each subtype has different characteristics and can help explain the behavior and prognosis in breast cancer.
Views: 278 Targeted Oncology
Charles Perou - Keynote Breast Cancer Genomics and Genetics
Watch on LabRoots at: http://labroots.com/user/webinars/details/id/88 It is now appreciated that breast cancer is not a single disease, but instead is a spectrum of tumor subtypes with distinct cellular origins, somatic changes and somewhat predictable clinical behaviors. Gene expression data coming from DNA microarrays, and now sequencing-based technologies, has provided additional insights into the biology of breast cancer that has resulted in the development of a number of clinically useful assays. Our work on breast tumors has led to a new molecular taxonomy that identifies at least five subtypes of breast cancers (Luminal A, Luminal B, HER2-enriched, Basal-like and Claudin-low) and a normal breast-like group. Known as the intrinsic subtypes, these groups have revealed critical differences in incidence, survival, metastatic site specificity, and response to treatment. In addition to the intrinsic subtypes, many other important prognostic and predictive gene expression-based profiles have been identified. These tests have lead to the identification of a subset of ER-positive patients that have an extremely good outcome, and thus, for whom adjuvant endocrine therapy alone appears sufficient. Alternatively, the remaining patients/subtypes including Luminal B, HER2-enriched and Basal-like, show significantly worse prognoses, although targeted therapies for HER2plus patients have greatly improved their outcomes. To address the need for the targeting of Luminal B and Basal-like subtypes, genome sequencing approaches are being employed to provide a means of rationally selecting new targeted agents. Other genomics findings with therapeutic potential include the discovery that a subtype of breast cancer (i.e. the Basal-like subtype) shows significant genetic and mRNA expression similarities with Serous Ovarian Cancers; these similarities include TP53 mutation (greater than 85% with almost no other commonly mutated genes), wide spread genomic instability, RB1-deficiency or Cyclin E1 amplification, BRCA1 inactivation, cMYC amplification, and high expression of AKT3. These common genetic/genomic features suggest that drug regimens that are used for Ovarian Cancer (i.e. a taxane and cis/carboplatin regimen) may also be effective on Basal-like breast cancers, which is being tested at a number of sites worldwide. Data from whole exome sequencing of Basal-like cancers will be presented and used as a model of how genome sequencing can contribute to the identification of potentially targetable driver mutations.
Views: 1824 LabRoots
Learning Breast Cancer Online: Staging of Breast Cancer
Speaker: Dr. Peter Choi
Identifying a Novel Diagnostic and Therapeutic Target for Metastatic Breast Cancer
With metastasis posing the primary challenge in the clinical management of breast cancer, there is high demand for effective diagnostic and therapeutic strategies focused on this facet of the disease. In this webinar, Dr. Michele Vitolo from the University of Maryland discusses the multi-pronged approach her lab has used to identify a tight correlation between acetylated alpha-tubulin levels and aggressive metastatic behavior in breast cancer. The implications for defining a simple prognostic biomarker in patients with breast cancer is presented. Other topics covered include: • An overview of microtentacles and their function in promoting metastatic reattachment of circulating tumor cells in distant tissues. • Using impedance-based label-free real-time xCELLigence® technology to quantitatively access the role of alpha-tubulin acetylation on breast cancer cell adhesion, invasion and migration properties • The correlation between increased alpha-tubulin acetylation and lymph node metastases, increased risk of disease progression, and death in patients Dr. Michele I. Vitolo obtained her B.S. at Franklin and Marshall College and her Ph.D. at the University of Maryland, Baltimore where she is currently an assistant professor of physiology in the School of Medicine. Dr. Vitolo has a long-standing interest in the molecular genetics of cancer. Her work has focused on PTEN loss and the progression of breast cancer. PTEN loss and the acquisition of PIK3CA activating mutations are often assumed to be reciprocal and mutually exclusive mutations, each resulting in the unregulated activation of the PI3K/Akt signaling pathway. However, she and her colleagues have recently reported differences in cytoskeletal structure and signaling between PTEN loss and PI3K activation. This finding could have new implications for patients with PTEN loss that are on current PI3K inhibitor therapies, possibly resulting in reduced drug efficacy. Currently, her research interests are focused on: 1) how the loss of PTEN promotes apoptosis-resistant cells which continue to respond cytoskeletally to the challenging environment of the bloodstream during metastasis, and 2) elucidating the cytoskeletal structural and signaling differences in cells with PTEN loss and PI3K activation. For more information, please visit: http://www.aceabio.com/products/xcelligence-rtca/ REFERENCES: 1. Matrone, M.A., Whipple, R.A., Thompson, K., Cho, E.H., Vitolo, M.I., Balzer, E.M., Yoon, J.R., Ioffe, O.B., Tuttle, K.C., Tan, M. and Martin, S.S. Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells. Oncogene. 2010 Jun 3;29(22):3217-27. 2. Whipple, R.A., Cho, E.H., Balzer, E.M., Matrone, M.A., Vitolo, M.I., Yoon, J.R., Ioffe, O.B., Tuttle, K.C., Yang, J. and Martin, S.S. Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement. Cancer Res. 2010 Oct 15;70(20):8127-37. 3. Yoon, J.R., Whipple, R.A., Balzer, E.M., Cho, E.H., Matrone, M.A. and Martin, S.S. Local anesthetics inhibit kinesin motility and microtentacle protrusions of human epithelial and breast tumor cells. Breast Cancer Res. Treat. 2011 Oct;129(3):691-701. 4. Vitolo MI, Boggs AE, Whipple RA, Yoon JR, Thompson K, Matrone MA, Cho EH, Balzer EM, Martin SS. Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin. Oncogene. 2013 Apr 25;32(17):2200-10. 5. Whipple RA, Vitolo MI, Boggs AE, Charpentier MS, Thompson K, Martin SS. Parthenolide and costunolide reduce microtentacles and tumor cell attachment by selectively targeting detyrosinated tubulin independent from NF-κB inhibition. Breast Cancer Res. 2013; 15(5):R83. 6. Charpentier MS, Whipple RA, Vitolo MI, Boggs AE, Slovic J, Thompson KN, Bhandary L, Martin SS. Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res. 2014 Feb 15;74(4):1250-60. 7. Perry NA, Vitolo MI, Martin SS, Kontrogianni-Konstantopoulos A. Loss of the obscurin-RhoGEF downregulates RhoA signaling and increases microtentacle formation and attachment of breast epithelial cells. Oncotarget. 2014 Sep 30;5(18):8558-68. 8. Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS. α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res. 2015 Jan 1;75(1):203-15. 9. Bhandary L, Whipple RA, Vitolo MI, Charpentier MS, Boggs AE, Chakrabarti KR, Thompson KN, Martin SS. ROCK inhibition promotes microtentacles that enhance reattachment of breast cancer cells. Oncotarget. 2015 Mar 20;6(8):6251-66.
Charles Perou - Untangling Triple Negative Breast Cancers
Simpósio Câncer de Mama Avanços e Perspectivas 2013
Molecular Subtyping with Breast Cancer
Stefan Gluck, M.D., Ph.D., medical professor at the University of Miami, discusses a study he published in the journal Breast Cancer Research and Treatment. The study showed that women who have the common Luminal A molecular subtype of breast cancer generally receive little benefit from preoperative chemotherapy – but still have good outcomes at the five-year point. Therefore, they can safely avoid chemotherapy and its sometimes debilitating side effects. The study underlines the importance of knowing the cancer’s molecular subtype so patients can be given the most appropriate therapy. Agendia’s BluePrint is a leading genomic test for determining breast cancer molecular subtype.
Views: 846 Agendia Inc
Breast Cancer Surgical Margins
Through a series of case studies, Rachael B. Lancaster, MD, gives an update on breast cancer surgical margins and discusses the recent changes in the landscape.
Views: 107 UAB Medicine
Adjuvant/Neoadjuvant Therapy for Breast Cancer: Updates and Molecular Predictors of Benefit
In this presentation from the 14th Annual Best of San Antonio - Breast Cancer: Bench to Bedside, Dr. Kathy S. Albain discusses updates in adjuvant and neoadjuvant therapy for the treatment of breast cancer, and elaborates on the latest data on predictors of benefit. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.
Views: 746 ImedexCME
Lady McMahon Memorial Public Lecture (2012): Breast cancer subtypes
Walter and Eliza Hall Institute 12 February 2012 Biology, biomarkers and therapeutic targets' and the speaker is Professor Robert Sutherland, Director of Cancer Research Program at the Garvan Institute of Medical Research. Jointly presented by the Walter and Eliza Hall Institute and the Australian Cancer Research Foundation.
Views: 2385 WEHImovies
Milan Breast Cancer Conference 2009: Basal-like and triple negative breast cancer
Breast Cancer Pathology Research Group Lead Investigator Dr Ian O. Ellis talking at the 11th Milan Breast Cancer Conference. Nottingham System for grading breast cancer. Investigative tumour biology. Not every triple negative breast cancer is basal-like and vice-versa.
Views: 524 ecancer
Pregnancy Obesity and Basal-like Breast Cancer Microenvironment
(Visit: http://www.uctv.tv/) Epidemiologic and experimental data have shown that a full term pregnancy reduces breast cancer risk. However, recent studies have suggested that while full term pregnancy does reduce risk for estrogen receptor and luminal breast cancers, pregnancy may actually increase risk of more aggressive basal-like breast cancers. There are complex relationships between age, race, parity, and obesity in observational human datasets making it difficult to translate these findings into public health messages. Melissa Troester, University of North Carolina Chapel Hill, addresses tumor heterogeneity, focusing specifically on the basal-like breast cancer subtype and the microenvironment changes that promote this breast cancer subtype during a vital window of susceptibility, the post partum period. Series: "Breast Cancer Prevention and Treatment" [Health and Medicine] [Show ID: 25025]
Find out your metaplastic breast cancer subtype
Message to doctors and patients of women with metaplastic breast cancer.
Views: 279 Bena Roberts
Fallacy of Breast Cancer Subtypes
Fallacy of Breast Cancer Subtypes Traditionally breast cancer is regarded as one disease. Recently a new theory proposes that breast cancer is a conglomerate of four different diseases or even more. This theory is based on some breast cancer manifestations, and ignores other important cancer attributes. I shall now show why this theory is false. First I shall describe the traditional theory and then confront it with the four breast cancers theory (4BT). The TNM system of cancer staging has a time arrow and describes cancer progression. Cancer progression is represented by a five dimensional vector with five components, Tumor ; Maturation arrest; Death probability; Drug resistance; Gene mutations. All are necessary for the description of cancer progression. In order to simplify the presentation, tumor is regarded as biomarker of the system. By observing tumor we may deduce the behavior of the system. The TNM trajectory stands for tumor burden growth which is proportional to the TNM system. The four breast cancer theory replaces the five component of the vector with one, gene mutations. Its four breast cancer are four states on the five dimensional system and not distinct disease. The 4BT theory is false since it is impossible to extrapolate a one dimensional theory into higher dimensions. This exercise illustrates the poor reasoning of modern medicine. You may apply it to other chronic diseases, like diabetes mellitus or essential hypertension and discover similar fallacies
Live breast cancer cells treated with Rho kinase inhibitor
MDA-MD-231 breast cancer cells (derived from metastatic, triple negative, Basal B subtype tumor) labeled with fluorescent CellTracker (Invitrogen) and treated with RhoA Kinase (ROCK) inhibitor Y-27632 (Sigma). Cells were imaged every 5 minutes at 20X using an automated spinning disk confocal microscope (PerkinElmer). Rho kinase inhibition results in loss of cell tension and increased ruffling, but migrating cells often fail to release cell-matrix adhesions in their tailing edges, leading to loss of polarized movement
Views: 557 Green Mouse
Luminal B Breast Cancer Progression : CXCR4/CXCL12 Signaling and Protumor Macrophages
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com, https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn , ,https://plus.google.com/u/0/+AlexandrosGSfakianakis , https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ , https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA , https://twitter.com/g_orl?lang=el, https://www.instagram.com/alexandrossfakianakis/, CXCR4/CXCL12 Signaling and Protumor Macrophages in Primary Tumors and Sentinel Lymph Nodes Are Involved in Luminal B Breast Cancer Progression via Disease Markers Luminal B breast cancers (BC) have a more aggressive behavior associated with a higher rate of tumor relapse and worse prognosis compared to luminal A tumors. In this study, we evaluated the involvement of specific epithelial-to-mesenchymal transition- (EMT-) and immune-related pathways in the dissemination of luminal B BC cells. The expression of 42 EMT- and immune-related genes was evaluated in matched sentinel lymph nodes (SLNs) analyzed by the one-step nucleic acid amplification assay (OSNA) and primary tumors of 40 luminal B BC patients by gene array and immunohistochemistry. The results were validated in an independent group of 150 luminal B tumors by immunohistochemistry and immunofluorescence and using gene expression data from 315 luminal B BC patients included in the Metabric dataset. We found that the expression of CXCR4 () and CD163 () was significantly upregulated in SLNs of recurrent luminal B BC patients. Luminal B primary tumors overexpressing CXCR4 were characterized by an increased expression of vimentin and a high content of CD163-positive macrophages. Bioinformatics analysis confirmed the correlation of CXCR4 with CXCL12, VIM, and CD163 expression and LN involvement. Our results suggest that the upregulation of the CXCR4/CXCL12 pathway and the presence of protumor macrophages in the primary tumor and SLNs sustain the aggressiveness of an important subgroup of luminal B BC. Add tags (Currently: A, Medicine by Alexandros G. Sfakianakis)
Kathy S. Albain: Patients with luminal A and B / HER2 negative breast cancer
Webcast from 13th St. Gallen International Breast Cancer Conference 13-16 March 2013: Patients with luminal A and B / HER2 negative breast cancer: Who benefits from chemotherapy? (Kathy S. Albain, USA)
Views: 953 oncoletter
Live breast cancer cells labeled with fluorescent dye
MDA-MB-231 cells (derived from metastatic, triple-negative breast cancer, Basal B genetic subtype) labeled with fluorescent CellTracker (Invitrogen). Imaged every 5 minutes using Opera automated spinning disk confocal microscope (PerkinElmer).
Views: 341 Green Mouse
Breast Cancer: Essentials for Clinicians on Breast Cancer
Fatima Cardoso, introduces the latest title in the ESMO Essentials for Clinicians series, which will be published on 2 November 2017. Published by the European Society for Medical Oncology
HALLMARKS OF CANCER 1: Protooncogenes, Oncogenes & Oncoproteins
In this video i have discussed 8 hallmarks of cancer and also about the role of oncogenes and oncoproteins in cancer ****Follow me***** http://ilovepathology.com/ Twitter : https://twitter.com/VijayPatho https://twitter.com/ilovepathology2 Facebook: https://www.facebook.com/ilovepathology/ Hallmarks of cancer 8 fundamental changes Protooncogenes , oncogenes & Oncoproteins Role of Oncogenes in cancer Definition A disorder of cell growth Triggered by a series of acquired mutations Affecting a single cell and its clonal progeny HALLMARKS OF CANCER 1. Self sufficiency in the growth Signals 2. Insensitivity to antigrowth/ growth inhibitory signals 3.Evasion of Apoptosis 4. Limitless Replicative Potential 5. Sustained Angiogenesis 6. The Ability to invade and Metastasize 7. Reprogramming Energy Metabolism 8. Evasion of Immune System enablers 9. Genomic Instability 10.Tumor promoting inflammation SELF SUFFICIENCY IN GROWTH SIGNALS Oncogenes: They promote unregulated proliferation/Autonomous cell growth (Self sufficiency in growth signals) The unmutated counterparts of Oncogenes are “proto oncogenes” Growth factors: Cancer cells develop growth self sufficiency ( Synthesize self responsive growth factors) Eg: a. PDGF – Glioblastomas b. TGF-α – Sarcomas c. FGF – Breast ca 2. Growth factor receptors:Cancer cells encode for growth factro receptors. a. EGF-receptor family: ERB-B1 (overexpression) Squamous cell carcinoma b. CSF-1 receptor: FMS (point mutation) – Leukemia c. PGDF receptor: PGDF-R (overexpression) - Gliomas 3. Signal transduction proteins – Receive growth promoting signals. Eg. RAS family (point mutation) – Ca colon, lung. Pancreas 4. Nuclear regulatory proteins: Transcriptional activators Eg: C-MYC (translocated) – Burkitt lymphoma N-MYC (Amplification) – Ca lung, 5. Cell cycle regulatory proteins: Eg: Cyclin D (Translocation) Ca breast, Ca esophagus CDK4 (Amplification) Melanoma -~-~~-~~~-~~-~- Please watch: "WARBURG EFFECT: Hallmark of CANCER. What, Why & How?" https://www.youtube.com/watch?v=LXaO59IqQm8 -~-~~-~~~-~~-~-
Views: 15249 ilovepathology
Live breast cancer cells treated with myosin II inhibitor
MDA-MD-231 breast cancer cells (derived from metastatic, triple negative, Basal B subtype tumor) labeled with fluorescent CellTracker (Invitrogen) and treated with the myosin II inhibitor blebbistatin (Sigma). Cells were imaged every 5 minutes at 20X using an automated spinning disk confocal microscope (PerkinElmer). Myosin II inhibition results in loss of cell tension and increased ruffling.
Views: 208 Green Mouse
How to Kill Off the Blood Supply to Cancer
Take Dr. Berg's Advanced Evaluation Quiz: http://bit.ly/EvalQuiz Your report will then be sent via email analyzing 104 potential symptoms, giving you a much deeper insight into the cause-effect relationship of your body issues. It's free and very enlightening. Dr. Berg talks about cutting off the blood supply to cancer. Angiogenesis is the process whereby the body makes new blood vessels and cancer needs its own blood supply. There are a natural plant based chemicals that inhibit the blood supply of cancer - which is explained in this video. REFERENCES: http://www.eattobeat.org/evidence/204/consumption-of-cruciferous-vegetables-reduces-the-risk-for-several-cancer-types.html http://pubs.acs.org/doi/abs/10.1021/jf050034w http://carcin.oxfordjournals.org/content/26/4/771.short file:///C:/Users/use/Downloads/or_22_6_1473_PDF.pdf https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/angiogenesis-inhibitors-fact-sheet Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional and natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government and the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning, published by KB Publishing in January 2011. Dr. Berg trains chiropractors, physicians and allied healthcare practitioners in his methods, and to date he has trained over 2,500 healthcare professionals. He has been an active member of the Endocrinology Society, and has worked as a past part-time adjunct professor at Howard University. DR. BERG'S VIDEO BLOG: http://www.drberg.com/blog FACEBOOK: http://www.facebook.com/DrEricBerg TWITTER: http://twitter.com/DrBergDC YOUTUBE: https://www.youtube.com/user/drericberg123 ABOUT DR. BERG: http://www.drberg.com/dr-eric-berg/bio DR. BERG'S SEMINARS: http://www.drberg.com/seminars DR. BERG'S STORY: http://www.drberg.com/dr-eric-berg/story DR. BERG'S CLINIC: https://www.drberg.com/dr-eric-berg/clinic DR. BERG'S HEALTH COACHING TRAINING: http://www.drberg.com/weight-loss-coach DR. BERG'S SHOP: http://shop.drberg.com/ DR. BERG'S REVIEWS: http://www.drberg.com/reviews The Health & Wellness Center 4709 D Pinecrest Office Park Drive Alexandria, VA 22312 703-354-7336 Disclaimer: Dr. Berg does not diagnose, treat or prevent any medical conditions; instead he helps people create their health to avoid health problems. He works with their physicians, which regular their medication. This video is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through my videos, blog posts, website information, I give suggestions for you and your doctor to research and provide general information for educational purposes only. The information provided in this video or site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. The Health & Wellness and Dr. Eric Berg, D.C. are not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this video or site.
Views: 93955 Dr. Eric Berg DC
Dr. Carey on Assays and Intrinsic Subtypes of Breast Cancer
Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses assays and intrinsic subtypes of breast cancer. For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Views: 120 Targeted Oncology
The role of axiliary node dissection in modern breast cancer surgery
Dr Viviana Galimberti speaks with ecancer at SABCS 2017 about the role of axillary node dissection in modern breast cancer surgery. She describes 10 year follow-up results from a trial of over 900 women who were surveilled for micro metastases in sentinel nodes, who were then randomised to axillary dissection or no surgery. Overall, Dr Galimberti describes the lack of significant difference between the arms in DFS and OS as further evidence to no longer conduct axillary node dissection for patients with micrometastatic sentinel nodes.
Views: 60 ecancer
Dr. Pat Whitworth on Importance of the Luminal Subtype in Breast Cance
Whitworth says that while it is generally perceived that the ER-positive/HER2-negative breast cancer patient population is the luminal subtype, 1 of every 5 of those patients would actually considered basal subtype. Whitworth says the reason this is important, is that the basal subtype normally has a much higher pathological complete response rate than the luminal subtype. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 92 Targeted Oncology
Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy
Prof Nielsen talks to ecancertv at SABCS 2015 about data showing that premenopausal women with invasive breast cancers of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy. In a prospectively performed retrospective analysis of the Danish Breast Cancer Cooperative Group (DBCG) 77B study, the aim was determine the predictive value of intrinsic breast cancer subtypes for response to adjuvant chemotherapy. Using tumour specimens from this randomised clinical trial, Prof Nielsen explains how data on the immunohistochemistry of the samples was used to identify the subtype of breast cancer and then assess the effect of adjuvant cyclophosphamide-based chemotherapy. Patients with luminal A breast tumours did not benefit from chemotherapy whereas patients with non-luminal A subtypes did. Prospective trial data are needed to confirm the findings.
Views: 388 ecancer
Charles M. Perou, PhD, Discusses Predicting Outcomes in Breast Cancer
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 119 Targeted Oncology
Benefits of Pomegranate Juice in Tamil | Mathulai Juice | Breast cancer | Healthy Life - Tamil.
Health Benefits of Pomegranate Juice: Pomegranate Juice Improves Your Heart Health: Pomegranate Juice Maintains Your Blood Sugar Levels: Pomegranate Juice Maintains Your Blood Pressure: Pomegranate Juice Reduces Risk Of Cancer: Pomegranate Juice Helps In Treating Diarrhoea And Dysentery: Antioxidants. ... Pomegranate juice contains higher levels of antioxidants than most other fruit juices. It also has three times more antioxidants than red wine and green tea. The antioxidants in pomegranate juice can help remove free radicals, protect cells from damage, and reduce inflammation Here are some of the potential benefits of pomegranate. Antioxidants. Pomegranates have been eaten throughout history for their health benefits. Vitamin C. Cancer prevention. Alzheimer's disease protection. Digestion. Anti-inflammatory. Arthritis. Heart disease. Cancer cells are cells that divide relentlessly, forming solid tumors or flooding the blood with abnormal cells. Cell division is a normal process used by the body for growth and repair. B. Basal Cell Carcinoma of the Skin - see Skin Cancer. Bile Duct Cancer. Bladder Cancer. Bone Cancer (includes Ewing Sarcoma and Osteosarcoma and Malignant Fibrous Histiocytoma) Brain Tumors. Breast Cancer. Bronchial Tumors, Childhood - see Unusual Cancers of Childhood. Burkitt Lymphoma - see Non-Hodgkin Lymphoma. The heart is a muscular organ in most animals, which pumps blood through the blood vessels of the circulatory system. Blood provides the body with oxygen and nutrients, as well as assists in the removal of metabolic wastes Blood pressure (BP) is the pressure of circulating blood on the walls of blood vessels. ... Normal resting blood pressure in an adult is approximately 120 millimetres of mercury (16 kPa) systolic, and 80 millimetres of mercury (11 kPa) diastolic, abbreviated "120/80 mmHg" Normal and diabetic blood sugar ranges. For the majority of healthy individuals, normal blood sugar levels are as follows: Between 4.0 to 5.4 mmol/L (72 to 99 mg/dL) when fasting. Up to 7.8 mmol/L (140 mg/dL) 2 hours after eating. Diabetes, often referred to by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body's cells do not respond properly to insulin, or both. In biology, immunity is the balanced state of multicellular organisms having adequate biological defenses to fight infection, disease, or other unwanted biological invasion, while having adequate tolerance to avoid allergy, and autoimmune diseases. Pomegranate Juice Improves Your Heart Health: ... Pomegranate Juice Maintains Your Blood Sugar Levels: ... Pomegranate Juice Maintains Your Blood Pressure: ... Pomegranate Juice Reduces Risk Of Cancer: ... Pomegranate Juice Helps In Treating Diarrhoea And Dysentery: #Immunity #GlowFace #Bloodpressure #bloodsugar #Diabetes #Cancercell #Cancer #Pomegranate Juice #Pomegranate #Mathulai Juice #Mathulai #Juice #Antioxidants #Diarrhoea #Dysentery #BreastCancer #tumors #bloodvessels #Digestion #HeartHealth
Molecular Testing in Breast Cancer: Will it Become Standard Practice? - Kimberly Allison, MD
How has gene expression profiling impacted the way we diagnose and treat breast cancers? Kimberly Allison, MD, Assistant Professor, Department of Pathology at the University of Washington discusses how research using gene expression signatures have been used to identify specific subtypes of breast cancer and how these are integrated into traditional classification schemes. In addition, we will explore the development of clinically available gene expression array-based tests that are designed to give prognostic and predictive information tailored to individual breast cancer patients and discuss current limitations of these tests." Kimberly Allison, MD
Views: 1181 UWTV
I Have Breast Cancer | Politics & Fashion
At 35, I was diagnosed with well-differentiated invasive ductal carcinoma. We're blessed because not only did we catch it early, but it's also slow to spread. This means my prognosis is great. Stay tuned to our #slaycancer videos to see the highs and lows of breast cancer treatment and learn about optimal breast health. Follow along on the blog and social media for daily insights. Don't forget to subscribe! ______________________________________ Find me on the interwebs: BLOG: politicsandfashionblog.com INSTAGRAM: @politicsandfshn TWITTER: @politicsandfshn FACEBOOK: Politics & Fashion ____________________________________
Views: 528 Politics & Fashion
20 early warning signs that cancer is growing in your body
20 early warning signs that cancer is growing in your body 1. Wheezing/shortness of breath Lung cancer patients remember noticing this as one of their first symptoms but didn't initially connect it to cancer. 2. Frequent fevers or infections Frequently a sign of leukemia, a cancer of the blood cells that starts in bone marrow. It causes the marrow to produce abnormal white blood cells that hinder your body's infection-fighting abilities. 3. Difficulty swallowing Most commonly associated with throat cancer, but can be a good indicator of lung cancer too. 4. Weakness and fatigue Such a common symptom of cancer that it should be looked at in combination with other symptoms to determine which it is. 5. Feeling full and unable to eat This is a sign of ovarian cancer. A loss of appetite even when you haven't eaten for a while is a tip-off. 6. Anorexia Could be an early sign of pancreatic cancer. A sudden disgust for coffee, wine or smoking can be linked to this as well. 7. Rectal bleeding or blood in stool Common sign of colorectal cancer. Blood in the toilet should be a big enough sign to see a doctor immediately. 8. Lumps in the neck, underarm or groin area Swollen lymph nodes indicate changes in the lymphatic system which can lead to cancer. 9. Excessive bruising or bleeding that doesn't stop Suggests abnormalities with the platelets and red blood cells, which can be a sign of leukemia. Leukemia cells crowd out red blood cells impairing your blood's ability to carry oxygen leading to clots. 10. Bloating or abdominal weight gain Ovarian cancer patients reported unexplained bloating that came on suddenly and continued for a significant amount of time. 11. Unexplained weight loss An early sign of colon and other digestive cancers. Also a sign of cancer that has spread to the liver, affecting your appetite and the body's ability to get rid of waste. 12. A red, sore, or swollen breast Indicates inflammatory breast cancer, unexplained changes should be told to a doctor immediately. A nipple that appears flattened, inverted or turned sideways had also been noticed by patients diagnosed with breast cancer. 13. Swelling of facial features Lung cancer patients have reported noticing puffiness, swelling or redness of the face. Small cell lung tumors commonly block blood vessels in the chest preventing blood from flowing freely to the head. 14. Sore/lump on the skin that bleeds, becomes crusty or doesn't heal Different types of skin cancer (melanoma, basal cell carcinoma and squamous cell carcinoma) can cause these, so be aware of any odd-looking growths or spots. 15. Changes in nails A brown/black dot under the nail can indicate skin cancer. Pale or white nails can be a sign of liver cancer. "Clubbing", which is the enlargement of the fingers with nails that curve down over the tips, can be a sign of lung cancer. 16. Unusually heavy or painful periods, bleeding between periods A common sign of endometrial or uterine cancer. A transvaginal ultrasound should be considered if the problem persists. 17. Chronic cough or chest pain Leukemia and lung tumors (among others), show symptoms that can mimic a bad cough or bronchitis. Some patients also reported a chest pain that extended to the shoulder and down their arm. 18. Pelvic/Abdominal pain Pain and cramping in the pelvis can be linked with the bloating signs of ovarian cancer. Leukemia also does this because it enlarges the spleen. 19. Pain in back or lower right side Often an early sign of liver cancer. Breast cancer can also be found through this as a breast tumor can press backward into the chest or spread to the spine/ribs. 20. Upset stomach Stomach cramps or a frequently upset stomach can be a sign of colorectal cancer. Subscribe ► https://goo.gl/1dVtUS Thank you for watching. Don't forget to comment, rate, and share this video. Subscribe for more videos from Intan Farisha. Finding the Balance Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License http://creativecommons.org/licenses/b... -~-~~-~~~-~~-~- Please watch: "do you remember the boy who smokes 40 cigarettes a day see what he looks like 8 years later!" https://www.youtube.com/watch?v=SwuQ4DOz7hg -~-~~-~~~-~~-~-
Views: 1668559 Intan Farisha
Young, black and at risk for breast cancer
African-American women under 50 are more commonly diagnosed with basal-like breast cancer (also known as triple negative breast cancer), a fast-growing subtype of breast cancer. These cancers make low levels of three proteins that are usually targeted in breast cancer treatment. Fewer treatment options are available for these cancers, so studies are needed to find better treatments for them. This video was developed by the UNC Breast Cancer and Environment Research Program (Grants #U01 ES019472 and 3 U01 ES019472-04S1) and the UNC Center for Environmental Health and Susceptibility (Grant # P30 ES010126), with funding, in part, from the National Institute of Environmental Health Sciences. The UNC Breast Cancer and Environment Research Program (BCERP) is a five-year initiative aimed at studying how obesity and other influences may affect susceptibility to an aggressive subtype of breast cancer, basal-like breast cancer. Visit the BCERP website at sph.unc.edu/bcerp/unc-bcerp/. For more information, contact Neasha Graves, UNC Breast Cancer and the Environment Research Program (BCERP). -neasha_graves@unc.edu -(919) 966-3746
Views: 251 uncpublichealth
Helga Christl, luminal A breast cancer survivor
Because she had luminal A breast cancer, Christl was able to participate in a clinical study providing an estrogen-lowering drug before surgery to decrease the size of her tumor and allow her to avoid mastectomy. She did not require chemotherapy after surgery and is doing well five years later. To learn more, visit http://www.siteman.wustl.edu.
Breast Cancer Update | Dr. Cary Hsu - UCLA Health
UCLA Health - Health Lectures http://uclahealth.org/calendar
Views: 6861 UCLA Health
Simple video of breast cancer stages, with images so it can be understood.
Views: 34 The HealthCafe'
Luminal Expansion
Transformed breast epithelial cell invading luminal space.
Views: 216 Rachel Davidowitz
Cancer The Forbidden Cures!
Astounding revelations of various cancer cures suppressed by reptilian/Illuminati AMA and FDA.
Views: 2991046 Richard Bruce
Dr. Charles M. Perou on the Evolution of Precision Medicine in Breast Cancer
Charles M. Perou, PhD, professor of Genetics, Pathology & Laboratory Medicine, Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses precision medicine in breast cancer and currently known biomarkers. Perou says as more biomarkers are found in the treatment paradigm of breast cancer and as the gene panels for the cancer become larger, medical professionals needs to stay abreast of current developments. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Views: 75 Targeted Oncology
What is an atypical cell ? |ASK it from Health FAQS
Normal cells go through quite a few changes before they become truly cancerous. They are now sending them for a atypical ductal hyperplasia (adh) is not form of breast cancer. It be that the cells on your biopsy are part of way along road towards becoming cancerous it causes proteins in to become hard and fixed, meaning they atypical could a cancer over time or increase person's risk 9, (the lobular hyperplasia (alh) usually negative for e cadherin. The american definition of atypical squamous cells undetermined significance atypical' in fine needle aspiration biopsy specimens benign decision to have thyroidectomy after found fna does anyone know what they mean by cells? Leukemia moles (dysplastic nevi) skincancer. Learn how to identify if a mole is melanoma sometimes it can be hard tell the difference between an atypical and early. What is an atypical cell falk copper cookware canada. Some melanomas begin within an atypical mole. Are atypical cervical cells cause for concern? Cancer center breast cancer topic what does having cell really mean? Dr susan love foundation. These moles are 10, atypical small acinar proliferation (asap) that is suspicious for b), which, on immunohistochemistry with the basal cell marker 34 e12, cells appear abnormal, but they aren't necessarily cancerous. Bal) specimens mimicking malignant atypical moles, also called dysplastic are very common. The presence of atypical cells is sometimes referred to as 'dysplasia. Cytojournal [serial online] 2006 [cited when the biopsy says atypical ductal hyperplasia and mentions increased unusually rapid growth of lobular cells is referred to as your doctor that pap test, or smear, was abnormal, it means test found some on cervix do not look normal. Googleusercontent search. Atypical ductal hyperplasia (adh) diagnosis johns hopkins breast atypical linked to high lifetime risk of cancer. An analysis will confirm the presence of atypical ductal hyperplasia cells in breast tissue 2, women with a build up abnormal have high lifetime risk cancer, according to new study by 20, 2005 total 149 fnab specimens from thyroid cysts containing were identified. Seventy five specimens with subsequent histologic atypia is a pathologic term for structural abnormality in cell, i. It or not be a precancerous indication associated bhatia a, dey p, kakkar n, srinivasan r, nijhawan r. Explaining your abnormal pap test iu health center. Cells are judged based 1, atypical cells not cancerous, but will increase a patient's risk for of the breast tissue and lobular hyperplasia, also known as alh, squamous undetermined significance is most common abnormal finding in pap test. I was under the impression that before biopsy, my chances were 80. This might cause you to worry that this means cancer, but atypical cells aren't necessarily cancerous. Mole biopsy atypical cells? What does it mean? Mothering forums. Atypical cells in bronchoalveolar lavage specimens from bone atypical moles american osteopathic college of dermatology pathology small acinar proliferation overview all a typical cancer cells? ? Messages compass. What does that my fine needle biopsy came back with atypical cells. In order for cells removed during a biopsy to be examined, they must put on slide, stained, and then looked at under microscope. If you have this finding, pap smear results atypical cells. It is used to describe atypical cells. Abnormal pap test topic overview webmd. Atypical cell in urine cytology a diagnostic dilemma atypical ductal hyperplasia and breast cancer risk by moose doc. Even normal aging can make cells appear abnormal atypical means that the are not entirely. My daughter is married and atypical moles (dysplastic nevi) are unusual benign that resemble melanoma. Malignant atypical cell in urine cytology a diagnostic dilemma. The degree found almost everywhere in body, atypical cells are usually not a cause for concern cell, centrioles of (sentr ls), n. Atypical cells in fine needle aspiration biopsy specimens of benign atypia wikipedia. Atypical cells are they cancer? Mayo clinic. How to spot an atypical mole skincancer. My endocrinologist suggested i remove the whole 8, 2007 as mentioned in a previous post don't know what htey are looking for but do that they found atypical cells. These are cells which appear mildly abnormal but the cause is unclear. An estimated one out of every 10 americans has at least atypical mole. Atypia on breast biopsy what does it mean? . 5, they found 'atypical cells which was neither a definite yes or no that there was cancer. Many factors can make normal cells appear atypical, including ascus atypical squamous of undetermined significance. Pap smear results atypical cells estronaut. Numerous nonneoplastic conditions of the lungs result in atypical cells bronchoalveolar lavage. If your report does not mention e cadherin, it means that 7, 2008 i am 17 years old and just had my first visit with the gynecologist. What is abnormal? Until a few years ago, pa
Views: 1897 BEST HEALTH Answers
Molecular Stratification of Triple Negative Breast Cancers
Lecture by Charles M. Perou, PhD This podcast focuses on the molecular stratification of triple negative breast cancers and the therapeutic implications of these classifications.
SuperPathway Analyses of Luminal and Basaloid Breast Cancers... - Christopher Benz
November 17-18, 2011 - The Cancer Genome Atlas' 1st Annual Scientific Symposium More: http://www.genome.gov/27546242
Dr. Nielsen Discusses the PAM50 Assay
Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.
Views: 289 OncLiveTV
444 Hz to kill cancer cells
In 1982, French composer Fabien Maman and Helene Grimal, a biologist at the National French Science Research Center, achieved amazing results from a joint study. They found that when healthy cells and uterine cancer cells placed in a petri dish were exposed to sound waves, the healthy cells did not change at all while the cancer cells changed in appearance. They began to shrink at sounds of 200 Hz, and as the frequency increased, the cells became round, and their color changed from red to pink. Surprisingly, when the sound frequency reached levels of 400 to 480 Hz, the cancer cells instead expanded and eventually burst. This sine wave frequency from 400 to 480 Hz would prove to be a kind of miracle frequency that kills and disintegrates cancer cells without harming normal cells. Specifically, the 444 Hz frequency is one of the “Solfeggio frequencies” capable of healing the body and mind. Now, there is a real chance that if this sound is applied directly to a cancerous area for a long period of time, the cancer cells will die and the disease cured. Loud volume increases this effect, but treatment is often administered with headphones placed directly to the affected area in consideration of surrounding patients. It is said that many cancer cells die after twenty minutes of applied radiation. Additionally, if you radiate drinking water with this frequency and drink a liter of it every day for 100 days or more, the healing effects will appear earlier. Besides mineral water, coffee or juice may also be vibrated to achieve this effect, but tea should be avoided because it cools the body. Cancer cell metabolism slows as the body warms and oppositely becomes more active as the body cools. Treatment and vibration water can be made not only with a personal computer but also using an iPad. It is this two-pronged approach of applying the frequency directly to the cancer-afflicted area to destroy cancer cells and flushing them out with vibration water that has the potential to cure cancer. Even those without cancer should do this once as a preventative measure. When tuning the reference frequency A from 440 Hz to 444 Hz, the music sounds less distorted and more elegant. Although this may not be related, it is nonetheless true that chords tuned to 444 Hz heal the mind and the body, whereas chords tuned to 440 Hz oppositely disrupt them. Europe’s top class orchestra is tuned to a frequency close to 444 Hz (around 442 Hz). Bathed body and soul in this pleasant chord, these master conductors are still waving their batons around well into their old age. On the other hand, there are many musicians who have fallen ill and left the world. Tragedy both mental and physical has befallen many musicians not only in the classical but also the jazz and the rock worlds as well. They may well be victims of the devil’s 440 Hz chord (dischord?).
Views: 181606 Sensui Muraki
HER-2+ Breast Cancer - Russell
Recorded at the 19th Annual Meeting of the Network of Oncology Clinicians and Researchers (NOCR) 2013. Earn CME at: http://elc.imedex.com
Views: 298 ImedexCME
Iodine and Cancer...What they are not telling you!!!!
Hello Friends, I am sharing my testimony and what I have learned from watching many hours of lectures on Iodine and Cancer from Doctors such as Dr. Brownstien, Dr. DeMaria, and Dr. Group. I noticed my age started reversing and my health problems going away. I found the article," Iodine VS Bromine, What They Are Not Telling You" and learned that Iodine was taken out of our food supply deliberately in 1970 by the Government and replaced with a very harmful substance called Bromine, which blocks your body from absorbing Iodine. Some of the results of this deficiency are IQ reduction, mental retardation, ADD ADHD, premature aging, arthritis, Obesity, tumors, Breast Cancer, Ovarian Cancer, IBS, to name a few. 70% of the population is severely deficient and does not know. Also, you would need to take 100 times the RDA to be effective according to these Doctors. Most people also don't know that since 1990 the FDA has been on the payroll for the pharmaceutical drug companies and is now over 60% funded by these drug companies they are suppose to be the watching for us. Please watch Gary Nulls FDA Exposed and A cure for Cancer 40 years ago while they are still available to view. I can be reached at IodineCuresCancer@gmail.com, if you would like to share your story. Please don't take my word for it...Do your own research on Iodine and Cancer. Everyone talks about the Health Care Crisis, but the profit motive in health care is what is really killing everyone. Thanks for watching. More videos to come...
Views: 46647 Felicia McCarron